| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
IN8bio, Inc.
13D/A
Amendment 4
INAB · 45674E109
|
4.0% |
12/29/2025
Event 12/22/2025
|
|||
| BIOS Fund II, LP | 0.2% | ||||
| BIOS Fund II QP, LP | 0.6% | ||||
| BIOS Fund II NT, LP | 0.1% | ||||
| BIOS Incysus Co-Invest I, LP | 0.3% | ||||
| BIOS Fund III, LP | 0.2% | ||||
| BIOS Fund III QP, LP | 1.3% | ||||
| BIOS Fund III NT, LP | 0.2% | ||||
| Bios Clinical Opportunity Fund, LP | 1.1% | ||||
| BP Directors, LP | 0% | ||||
| Bios Equity Partners, LP | 0% | ||||
| Bios Equity Partners II, LP | 1.3% | ||||
| BIOS Equity Partners III, LP | 1.7% | ||||
| Bios Equity COF, LP | 1.1% | ||||
| Cavu Management, LP | 2.9% | ||||
| BIOS Capital Management, LP | 4.0% | ||||
| Cavu Advisors, LLC | 2.9% | ||||
| BIOS Advisors GP, LLC | 4.0% | ||||
| Kreis Leslie W. | 2.9% | ||||
| Fletcher Aaron G.L. | 4.0% | ||||
|
IN8bio, Inc.
13D/A
Amendment 3
INAB · 45674E109
|
10.0% |
5/8/2025
Event 5/2/2025
|
|||
| Bios Fund II, LP | 0.6% | ||||
| Bios Fund II QP, LP | 2.1% | ||||
| Bios Fund II NT, LP | 0.3% | ||||
| Bios Incysus Co-Invest I, LP | 1.1% | ||||
| Bios Fund III, LP | 0.6% | ||||
| Bios Fund III QP, LP | 4.1% | ||||
| Bios Fund III NT, LP | 0.7% | ||||
| Bios Clinical Opportunity Fund, LP | 3.3% | ||||
| BP Directors, LP | 0.1% | ||||
| Bios Equity Partners, LP | 0.1% | ||||
| Bios Equity Partners II, LP | 4.1% | ||||
| Bios Equity Partners III, LP | 5.4% | ||||
| Bios Equity Cof, LP | 3.3% | ||||
| Cavu Management, LP | 9.6% | ||||
| Bios Capital Management, LP | 10.0% | ||||
| Cavu Advisors, LLC | 9.6% | ||||
| Bios Advisors GP, LLC | 9.9% | ||||
| Leslie W. Kreis | 9.6% | ||||
| Aaron G.L. Fletcher | 10.0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.